Bayer’s Commitment in Ophthalmology

Zig Lang, MD, PhD
Vice President and Head of Medical Affairs & Pharmacovigilance,
Bayer HealthCare Company Ltd.
Bayer’s commitment to addressing unmet needs in ophthalmology

Bayer is helping reduce the number of people impacted globally by visual impairment through innovative products and research.

‘Science For A Better Life’ not only means a commitment to researching and developing innovative medicines, but also to preventing vision loss and preserving healthy vision, through awareness and education.
There remain unmet needs in ophthalmology

- Increase awareness of regular eye screenings
- Establish proactive and ongoing treatment
- Reduce the treatment burden
- Increase therapeutic efficacy
- Discover therapies for currently untreated eye diseases

Universal access to diagnostic screening and appropriate treatments
Our long-term commitment to ophthalmology aims to improve the quality of life of patients.

1. Anti-VEGF therapy
2. Internal pipeline
3. Fostering research
4. Collaborations
We are improving outcomes for five of the leading causes of vision loss in the working-age and elderly populations.

- **Wet AMD**
  - VIEW 1 (Phase III, US)
  - VIEW 2 (Phase III, ROW)
  - SIGHT (Phase III, China)

- **CRVO + BRVO**
  - COPERNICUS (Phase III, US)
  - GALILEO (Phase III, ROW)
  - VIBRANT (BRVO Phase III, US/Japan)

- **DME**
  - DA VINCI (Phase II, US & ROW)
  - VISTA (Phase III, US & ROW)
  - VIVID DME (Phase III, Asia incl. China, Russia)

- **Myopic CNV**
  - myrror (Phase III, Japan/Asia Pacific)
We continue to expand our pipeline through R&D.

Our expansion is focused on discovery, dedicated to establishing a competitive edge and portfolio in exudative (wet) diseases and...

...a broader presence that includes non-exudative (dry) diseases and other promising specialty segments.
Supporting the ophthalmology community to address unmet needs and improve patient outcomes

**Vision Academy**
Providing a forum for retina specialists to exchange knowledge and build best practices, addressing new challenges and treatments in ophthalmology

**74 specialists in 31 countries**
Member from China:
- Prof. Li Xiaoxin, Peking University People’s Hospital

**Ophthalmology Global Preceptorship Program**
Facilitating engagement and learning with ophthalmologists by sharing knowledge and best practices in the in-clinic management of retinal diseases

**5 centers in 5 continents**
6 attendees from China in 2015:
- Save Sight Institute, Australia
- University of Chicago, USA
Facilitating scientific progress in eye care

**Global Ophthalmology Awards Program**

The first worldwide program that helps the research community in their quest for breakthroughs that can significantly impact patients’ lives through research grants and training in retinal ophthalmology

- **35 emerging investigators**
- in **17 countries since 2012**

**EyeFocus Accelerator**

Supporting the world’s first eye care focused tech accelerator for startups addressing unmet needs surrounding the detection, prevention and support for people with visual impairment or blindness

- **Med-tech startups**
- from **13 countries**
Partnering to improve the lives of patients with visual impairment

Jointly developing an innovative next generation therapy for retinal diseases targeting different pathways

Jointly researching and developing drugs for back-of-the-eye diseases including age-related macular degeneration and Stargardt’s disease

Collaborating with Inception Sciences and Versant Ventures to develop treatment options, focused on a novel target and pathway for wet AMD and geographic atrophy

Research collaboration on *in vivo* models of dry AMD
The power of global collaborations

Our commitment to ‘Science For A Better Life’ not only means a commitment to researching and developing innovative medicines, but also to preventing vision loss and preserving healthy vision through awareness and education.

<table>
<thead>
<tr>
<th>Diabetic Retinopathy (DR) Barometer Project</th>
<th>RAAB (Rapid Assessment of Avoidable Blindness)</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="IFA" /></td>
<td><img src="image2" alt="The Fred Hollows Foundation" /></td>
</tr>
<tr>
<td><img src="image3" alt="IAPB" /></td>
<td><img src="image4" alt="Orbis" /></td>
</tr>
<tr>
<td><img src="image5" alt="International Diabetes Federation" /></td>
<td><img src="image6" alt="Sightsavers" /></td>
</tr>
<tr>
<td><img src="image7" alt="The New York Academy of Medicine" /></td>
<td><img src="image8" alt="... and more" /></td>
</tr>
</tbody>
</table>

Respondents from China:
- 71 patients
- 42 clinicians

RAAB in China:
- 9 provinces
- Supported by NHFPC
Provide support through Corporate Social Responsibilities programs

Bayer employees in China engage in volunteer services and provide help where needed

- Audio book recording for vision impaired children
- Video telling (Cinema at Heart)
- Assisting drama play
- Beijing Marathon
- Athletic meeting of vision impaired person